

# Sunitinib for Patients with Primary Sarcomas of the CNS

A study for adults with gliosarcomas and primary sarcomas of the CNS.



## + Objective

National Cancer Institute (NCI) researchers are conducting a study of patients with primary sarcomas of the central nervous system (CNS).

This study will test if the cancer drug sunitinib, which is approved by the U.S. Food and Drug Administration to treat other rare cancers, slows or stops the spread of cancer cells in the brain or spine.

### What the study involves:

- Physical and neurological examination
- EKG to evaluate the heart
- Patient questionnaire about health and symptoms
- MRIs and neurological function tests
- Study of tumor tissue from prior surgeries
- Your samples used for a health evaluation
- Receive drug sunitinib for 2 weeks and then take none for 1 week. These 3 weeks equal 1 cycle.
- A final evaluation one month after final treatment cycle

### You can participate if you:

- Are age 18 or older
- Are diagnosed with a gliosarcoma or primary sarcoma of the CNS that has returned
- Have been treated with standard therapies
- Have normal organ and marrow function
- Are not pregnant or breastfeeding

You can participate in this study by visiting the NIH at Bethesda, Maryland for a clinical assessment.

## Questions?

Contact us at (240) 760-6010 or [NCINOBReferrals@mail.nih.gov](mailto:NCINOBReferrals@mail.nih.gov)

[clinicaltrials.gov](https://clinicaltrials.gov) ID: NCT03641326

